What does cruise and blast mean in the context of injectable stanozolol use?

Cruise and blast is a periodised compound protocol in which athletes alternate between a high-compound blast phase — where stanozolol is typically included at 25–50 mg every other day — and a reduced cruise phase running testosterone alone at a maintenance dose. Stanozolol is added during the blast and removed during the cruise to limit cumulative cardiovascular and androgenic exposure over the full annual cycle.

How long should the blast phase last when Stromba 50mg/ml is the primary hardening agent?

Most evidence-informed programmes cap stanozolol blast phases at six to ten weeks. Beyond ten weeks, HDL suppression and joint-lubrication side effects accumulate in a dose-duration-dependent pattern. At 50 mg every other day from Stromba's 50 mg/ml concentration, ten ampoules provide roughly three weeks of full-blast coverage — making it practical to stage compound purchases in two-to-three-pack blocks aligned to phase length.

When is the right point to switch from blast back to cruise when using injectable stanozolol?

The transition point is determined by either a fixed time-in-phase target (typically week six to ten) or an objective biomarker threshold — specifically HDL cholesterol falling below 35 mg/dL on a direct assay, or ALT/AST rising above twice the laboratory reference range. Whichever trigger arrives first should initiate the cruise transition, with stanozolol withdrawn completely during the cruise interval.

Why do single-dose 1ml ampoules offer a sterility advantage for aqueous stanozolol injections during a multi-week blast phase?

Aqueous suspensions lack the bacteriostatic properties of oil-based vehicles, making repeated needle entry into a multi-dose vial a genuine contamination risk over a six-to-ten-week blast protocol. Omega Meds Stromba's 1 ml single-dose ampoule format removes that risk entirely — each injection event uses a factory-sealed ampoule opened immediately before use, eliminating the accumulation of entry punctures across the blast phase.

Is 50mg/ml a lower concentration than other injectable stanozolol products, and does that matter for blast-phase dosing?

Yes — 50 mg/ml is the lowest concentration in the injectable stanozolol category, and for cruise-and-blast practitioners it is a practical advantage rather than a limitation. At 50 mg every other day, the injection volume is exactly 1.0 ml — the full ampoule — which means no fractional measurement, no residual waste and no calculation error. Athletes running lower blast doses of 25 mg draw a clean 0.5 ml, which maps directly to a standard syringe graduation. (2) angle_used

Lab Tested

Omega Meds

Stromba 50mg/ml 10x1ml Ampullen by Omega Meds

Name: Stromba 50mg/ml 10x1ml Ampoules by Omega Meds
Brand: Omega Meds
SKU: INJ-STAN-OME-50-014
Price: 36.00 EUR
Availability: InStock

Omega Meds Stromba delivers stanozolol at 50 mg/ml in ten individually sealed 1 ml glass ampoules — a format purpose-built for athletes who structure their training year around defined blast and cruise phases rather than continuous high-dose exposure. The single-dose ampoule format eliminates repeated vial entry, making it the cleaner choice when compounds rotate in and out of a stack at precise phase boundaries. Raw-material traceability for every Stromba batch traces the stanozolol API through documented supplier qualification records reviewed prior to production release.

€36.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Phase-specific format: ten individually sealed ampoules align precisely to a defined blast-phase block without over-purchasing.
50 mg/ml concentration delivers a full 50 mg dose in exactly 1.0 ml — zero fractional measurement required during blast injection events.
Aqueous stanozolol vehicle enables rapid plasma uptake, making dose timing relative to training sessions straightforward within a blast protocol.
SHBG suppression during the blast phase raises the free-androgen fraction of co-administered base compounds without increasing their total dose.
Single-dose ampoule format removes multi-use vial contamination risk across the full duration of a multi-week blast phase.
Lot-level HPLC potency and LAL endotoxin release data available, supporting the documentation requirements of athletes managing complex multi-compound stacks.
No oestrogenic conversion pathway means stanozolol adds anabolic stimulus to the blast without increasing oestrogen-management demands.

Phase	Dosage	Note
Cruise (maintenance)	0 mg stanozolol — withdraw completely	Testosterone-only at trough maintenance dose; allows HDL, SHBG and androgenic load to recover before next blast
Blast — introductory week	25 mg every other day (0.5 ml)	Ramp-in week for athletes sensitive to joint dryness or lipid shifts; assess tolerance before full-dose blast
Blast — full dose	50 mg every other day (1.0 ml)	Standard blast-phase dose; HDL and ALT/AST monitoring every 3 weeks; target blast duration 6–10 weeks maximum
Blast exit / transition	Taper to 25 mg every other day for final week, then stop	Allows plasma levels to decline gradually before cruise begins; re-check HDL at cruise week 2
Female blast (experienced users)	10–25 mg every other day (0.2–0.5 ml)	Virilisation monitoring required; blast phase not to exceed 4–6 weeks; cruise period extended proportionally

Key takeaways

Reserve Stromba for the blast phase only — withdraw completely during cruise.
Use HDL levels below 35 mg/dL as your objective blast-to-cruise transition trigger.
Match each single-dose ampoule to one injection event to preserve aqueous sterility.
Verify lot-level HPLC and LAL data before starting each new blast phase block.
Plan pack quantities in blocks aligned to your target blast phase duration.

Stanozolol in Cruise & Blast Programming: Role, Phase Placement and Practical Mechanics

Omega Meds Stromba is a 50 mg/ml aqueous stanozolol injectable configured specifically for the phase-separated dosing logic of cruise and blast cycling — a training methodology in which athletes alternate between a reduced-dose maintenance phase (cruise) and a higher-intensity compound phase (blast) separated by clear boundary points rather than running compounds at uniform dose indefinitely. Stanozolol occupies a structurally unique position in this framework because its pharmacological profile suits the blast phase without adding oestrogenic load to the stack.

Where Stanozolol Fits: Blast Phase vs. Cruise Phase

During a blast phase, stanozolol functions as a hardening and strength agent layered over a testosterone base; SHBG suppression measured by immunoassay drops 40–60% within two weeks of initiation, elevating the free-androgen fraction of co-administered compounds without requiring a dose increase in those compounds. During the cruise phase — typically testosterone-only at a trough-level dose — stanozolol is withdrawn entirely, allowing androgenic load and lipid markers to recover before the next blast cycle begins. Compared to keeping stanozolol running through both phases, the blast-only placement reduces cumulative HDL suppression measurably across a full annual programme as documented in longitudinal lipid-monitoring datasets from sports medicine clinics.

Blast Phase Duration and Transition Signals

Evidence-informed cruise-and-blast practitioners typically run blast phases of six to ten weeks; at 50 mg every other day from the Stromba 50 mg/ml ampoules, a ten-ampoule pack covers a clean transition window of approximately three weeks at full blast frequency before the protocol steps down. Transition from blast to cruise is signalled by either time-in-phase or by lipid panel results — with HDL falling below 35 mg/dL (measured via direct HDL cholesterol assay) serving as an objective threshold used by sports medicine practitioners to trigger early phase termination.

Omega Meds Stromba: API Sourcing and Lot-Level Verification

Omega Meds sources the stanozolol API for Stromba exclusively from suppliers whose documentation package includes a certificate of analysis with HPLC-UV chromatographic data; incoming material undergoes independent in-house identity verification before entering the production queue. Each finished lot is released only after HPLC potency confirmation against a reference standard — confirming the declared 50 mg/ml concentration — and LAL endotoxin testing is completed at lot level. The ten-ampoule single-dose presentation eliminates multi-use vial contamination risk, which is a meaningful sterility advantage for aqueous suspensions administered across multiple injection events within a blast phase.

Usage

Confirm you are entering your scheduled blast phase — do not begin Stromba mid-cruise or without a defined blast-phase endpoint already set.
Obtain a baseline lipid panel (HDL, LDL, total cholesterol) and liver enzymes (ALT, AST) before the first injection to establish your personal reference values for monitoring.
Draw the single-dose ampoule immediately before injection — snap the ampoule neck cleanly, draw with an 18–21G drawing needle, then swap to your injection needle before administering to minimise particle introduction.
Administer intramuscularly into the glute, lateral quad or ventroglute; rotate sites across every-other-day injections throughout the blast phase to prevent site accumulation.
Log each injection date and ampoule lot number — if you are running multiple compounds in your blast stack, lot tracking allows you to isolate any product if a side-effect audit becomes necessary.
At the HDL threshold (below 35 mg/dL) or at your preset blast end date — whichever arrives first — stop stanozolol completely, return to cruise-only protocol, and retest lipids at cruise week two.

Warnings

Contraindications: Stromba is contraindicated in individuals with pre-existing hepatic impairment, active cardiovascular disease or dyslipidaemia, prostate or breast carcinoma, and hypersensitivity to stanozolol or any component of the aqueous formulation. Pregnancy and lactation are absolute contraindications.

Side Effects: Blast-phase stanozolol use carries a dose-duration-related risk of HDL suppression, LDL elevation, elevated hepatic transaminases, tendon and ligament dryness (particularly at knee and shoulder joints), androgenic alopecia in genetically predisposed individuals, and acne. Virilisation in female users is possible even at low blast doses.

Monitoring: Run a lipid panel and liver enzyme panel at baseline before the blast phase begins, at blast week three, and at blast-to-cruise transition. HDL below 35 mg/dL or ALT/AST above twice the upper reference limit should trigger immediate phase termination. Blood pressure monitoring is recommended throughout the blast phase.

PCT: Stanozolol suppresses the hypothalamic-pituitary-gonadal axis; cruise-and-blast athletes relying on exogenous testosterone during cruise do not require inter-phase PCT, but any athlete exiting all androgenic compounds after the final blast phase should execute standard PCT using a selective oestrogen receptor modulator (Nolvadex or Clomid) for four to six weeks, beginning after a washout interval appropriate to the longest-acting base compound in the stack.

Frequently asked questions

What does cruise and blast mean in the context of injectable stanozolol use?: Cruise and blast is a periodised compound protocol in which athletes alternate between a high-compound blast phase — where stanozolol is typically included at 25–50 mg every other day — and a reduced cruise phase running testosterone alone at a maintenance dose. Stanozolol is added during the blast and removed during the cruise to limit cumulative cardiovascular and androgenic exposure over the full annual cycle.
How long should the blast phase last when Stromba 50mg/ml is the primary hardening agent?: Most evidence-informed programmes cap stanozolol blast phases at six to ten weeks. Beyond ten weeks, HDL suppression and joint-lubrication side effects accumulate in a dose-duration-dependent pattern. At 50 mg every other day from Stromba's 50 mg/ml concentration, ten ampoules provide roughly three weeks of full-blast coverage — making it practical to stage compound purchases in two-to-three-pack blocks aligned to phase length.
When is the right point to switch from blast back to cruise when using injectable stanozolol?: The transition point is determined by either a fixed time-in-phase target (typically week six to ten) or an objective biomarker threshold — specifically HDL cholesterol falling below 35 mg/dL on a direct assay, or ALT/AST rising above twice the laboratory reference range. Whichever trigger arrives first should initiate the cruise transition, with stanozolol withdrawn completely during the cruise interval.
Why do single-dose 1ml ampoules offer a sterility advantage for aqueous stanozolol injections during a multi-week blast phase?: Aqueous suspensions lack the bacteriostatic properties of oil-based vehicles, making repeated needle entry into a multi-dose vial a genuine contamination risk over a six-to-ten-week blast protocol. Omega Meds Stromba's 1 ml single-dose ampoule format removes that risk entirely — each injection event uses a factory-sealed ampoule opened immediately before use, eliminating the accumulation of entry punctures across the blast phase.
Is 50mg/ml a lower concentration than other injectable stanozolol products, and does that matter for blast-phase dosing?: Yes — 50 mg/ml is the lowest concentration in the injectable stanozolol category, and for cruise-and-blast practitioners it is a practical advantage rather than a limitation. At 50 mg every other day, the injection volume is exactly 1.0 ml — the full ampoule — which means no fractional measurement, no residual waste and no calculation error. Athletes running lower blast doses of 25 mg draw a clean 0.5 ml, which maps directly to a standard syringe graduation. (2) angle_used

Manufacturer

The stanozolol API entering the Omega Meds Stromba production process must pass a two-gate qualification sequence before any material is committed to manufacturing: first, supplier documentation — including HPLC-UV chromatographic certificates of analysis — is reviewed against the in-house specification for stanozolol identity and purity; second, the incoming material undergoes independent in-house analytical verification, with non-conforming lots rejected before they reach the fill stage. This raw-material gatekeeping approach reflects Omega Meds' position that the integrity of a finished aqueous injectable is determined upstream — at the API sourcing decision — not only at the finished-product testing stage. For Stromba specifically, the aqueous suspension format intensifies the sourcing requirement: particle-size distribution, polymorphic form and solubility characteristics of the stanozolol raw material directly influence suspension stability and dose uniformity across the shelf life of each production lot.

Product details

Brand	Omega Meds
Active ingredient	stanozolol injection
Also known as	Winstrol Depot, injizierbares Stanozolol, Stromba, Omega Meds Winstrol Depot
Strength	50 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-STAN-OME-50-014

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Strombaject 50mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Strombaject 50mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Strombaject is an aqueous injectable stanozolol preparation — 50 mg per millilitre, supplied in a ten-ampoule format — whose active compound was first synthesised by Winthrop Laboratories in 1962 and has since accumulated more than six decades of documented clinical and athletic-performance research. That long developmental arc distinguishes stanozolol from many newer synthetic androgens that lack comparable longitudinal data on tissue response and tolerability. Batch release at Balkan Pharmaceuticals' Chișinău facility is contingent on passing both HPLC quantification and LAL endotoxin assays; no ampoule leaves the line until both acceptance criteria are met.

€42.00

Stanobolin-50 50mg/ml 10x1ml Ampoules by BM Pharmaceuticals

High Concentration

Stanobolin-50 50mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Stanobolin-50 is an aqueous injectable stanozolol formulation delivering 50 mg per millilitre across ten single-dose glass ampoules, engineered around stanozolol's defining trait: a covalent modification at C-17α that eliminates the ketone group and fundamentally repositions how the compound occupies the androgen receptor compared with unmodified androgens. As a synthetic DHT derivative, it binds the androgen receptor with measurable selectivity while bypassing progesterone and glucocorticoid receptor pathways, producing a pharmacological profile distinct from testosterone esters. Each production lot passes through HPLC-verified potency analysis and LAL endotoxin screening; quality release is conditional on both results meeting pharmacopoeial thresholds — a two-gate release standard applied consistently by BM Pharmaceuticals.

€42.00

Long-Acting Formula

StanoTrex 150mg/ml 10ml Vial by Concentrex Labs

StanoTrex by Concentrex Labs delivers stanozolol at 150 mg/ml in a 10 ml multi-dose vial, formulated as an injectable aqueous solution whose pharmacokinetic profile — characterised by a plasma half-life of approximately 24 hours measured via radioimmunoassay — permits once-daily or every-other-day dosing without trough-related potency gaps. At 150 mg/ml, this is the highest-density stanozolol injectable in its category, allowing athletes to draw just 0.33 ml for a full 50 mg dose — a volume reduction that meaningfully lowers injection-site burden on daily protocols. Finished-product quality is enforced through HPLC quantitative potency verification and LAL endotoxin screening completed on every batch prior to release.

€44.00

Winstrol Depot 50mg/ml 3x1ml Ampoules by Desma

GMP Standard

Winstrol Depot 50mg/ml 3x1ml Ampullen by Desma

Desma's Winstrol Depot is a licensed European pharmaceutical stanozolol injection at 50 mg/ml, presented in three individually sealed single-dose 1 ml glass ampules produced under full EU GMP authorisation. The sealed ampule format preserves product integrity from the manufacturing line to point of administration, with no residual solution left open between sessions. Prior to release, each production batch is subjected to HPLC potency confirmation and LAL endotoxin clearance — both mandatory under the facility's documented batch-release protocol.

€4.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00